Quick Takeaways:
- Optiscan has launched InSpecta, its first commercial veterinary microscopic imaging device, in the US following submission of its regulatory dossier to the FDA Center for Veterinary Medicine (CVM), marking the company’s entry into commercial sales.
- Designed for veterinary practices, InSpecta provides real-time cellular-level imaging at the point of care, enabling faster clinical decision-making, improved workflow efficiency, and new in-house diagnostic service opportunities across specialist, general, and mobile veterinary settings.
- The device is being showcased at the 2026 American Veterinary Medical Association (AVMA) Convention and establishes a regulatory and commercial pathway for Optiscan’s future imaging products targeting both veterinary and human healthcare markets.
Why It Matters?
By bringing real-time, cellular-level microscopic imaging into everyday veterinary workflows, without lab delays, InSpecta gives specialist, general, and mobile practices a new in‑house diagnostic capability that can speed decision-making and create billable services, which should drive adoption in higher-end clinics and raise client expectations for advanced diagnostics. The FDA CVM dossier and AVMA 2026 launch validate Optiscan’s ability to navigate US regulation and establish a repeatable path for future devices, so this move effectively opens a new advanced-diagnostics segment in the veterinary market.
Source: Optiscan
